In October of 2023, the American Heart Association (AHA) published a scientific statement and advisory that defined a novel entity, cardiovascular-kidney-metabolic (CKM) syndrome.1,2 The overall framework proposes that a substantial proportion of cardiovascular disease (CVD) burden is attributable to a syndrome that extends in stages from obesity (stage 1) to metabolic/kidney risk factors for CVD (diabetes mellitus, chronic kidney disease [CKD], hypertension, and dyslipidemia) (stage 2), subclinical CVD (state 3), and finally clinical CVD (stage 4).